- active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
United States · Australia · Austria - recruitingPHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
This study looks at new ways to give a medicine called sonrotoclax for blood cancers like Chronic Lymphocytic Leukemia (CLL). We want to find the safest and most effective starting dose schedule, often with another medicine called zanubrutinib, to help patients.
United States · Australia · France - recruitingPHASE3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
This study is looking at a new combination of treatments for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares a new drug called Nemtabrutinib with Venetoclax against a standard treatment, to see if the new combination is better at stopping the cancer from growing.
United States · Argentina · Australia